XOMAP vs BCYC vs PRTC vs NUVB vs RCUS

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). XOMA Corporation (XOMAP) offers the better valuation at 17. 3x trailing P/E (32. 3x forward), making it the more compelling value choice. Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, XOMA Corporation (XOMAP) delivered a total return of +42.

5%, compared to -84. 6% for Bicycle Therapeutics plc (BCYC). Over 10 years, the gap is even starker: XOMAP returned +51. 0% versus BCYC's -59. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.

03β versus Nuvation Bio Inc. 's 1. 97β — meaning NUVB is approximately 5895% more volatile than XOMAP relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 3% versus 127% for XOMA Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: XOMA Corporation grew EPS 188. 5% year-over-year, compared to -24. 0% for PureTech Health plc. Over a 3-year CAGR, XOMAP leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Corporation (XOMAP) is the more profitable company, earning 60.

8% net margin versus -23. 6% for PureTech Health plc — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMAP leads at 21. 8% versus -21. 1% for PRTC. At the gross margin level — before operating expenses — BCYC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRTC: 235.

9% to $57. 00.

In this comparison, XOMAP (1.

2% yield) pays a dividend. BCYC, PRTC, NUVB, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

03), 1. 2% yield). Nuvation Bio Inc. (NUVB) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XOMAP: +51. 0%, NUVB: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XOMAP is a small-cap high-growth stock; BCYC is a small-cap high-growth stock; PRTC is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. XOMAP pays a dividend while BCYC, PRTC, NUVB, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.